{"id":"W4416391641","doi":"10.1016/j.annonc.2025.09.064","title":"LBA52 Nofazinlimab combined with lenvatinib versus placebo plus lenvatinib as first-line therapy for unresectable or metastatic hepatocellular carcinoma: A phase III, randomized, double-blind, multiregional study (CS1003-305)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; European Association for the Study of the Liver; Servier; Gilead Sciences; Hospices Civils de Lyon; Deutsche Krebshilfe; Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft; Les Laboratories Pierre Fabre; Eisai; Ipsen; Jazz Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Oncolytics Biotech; Boston Scientific Corporation; American Association for the Study of Liver Diseases; Bayer HealthCare; Kowa Company; Sanofi; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Placebo; Hepatocellular carcinoma; Phases of clinical research; Clinical trial; Monoclonal","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001008519,0.001621922,0.00312351,0.0005406134,0.0003407508,0.001083224,0.0009258699,0.001325198,0.006380819],"category_scores_gemma":[0.0008643722,0.0006810569,0.001844609,0.0004420242,0.001049125,0.001010694,0.0003571974,0.003096681,0.001371651],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008887253,"about_ca_system_score_gemma":0.001392263,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001577275,"about_ca_topic_score_gemma":0.004168629,"domain_scores_codex":[0.9996656,0.0001402824,0.00001699748,0.00006958022,0.00002641831,0.00008108239],"domain_scores_gemma":[0.9995366,0.00008548721,0.00009578142,0.00003864177,0.0000252883,0.0002181515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9654006,0.008525449,0.0004239728,0.0004570388,0.0008816012,0.000019345,0.00002348932,0.0003884496,0.004890193,0.00008432602,0.001007164,0.01789843],"study_design_scores_gemma":[0.910167,0.0855639,0.001872866,0.00002485497,0.0005497954,0.00002543177,0.00002054408,0.0005084216,0.0007053809,0.00009251243,0.0004518095,0.00001748722],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873288,0.004842676,0.0006274553,0.0007259105,0.0008078805,0.001654954,0.001213221,0.0002903382,0.002508787],"genre_scores_gemma":[0.9873117,0.002732107,0.001197725,0.0009751238,0.0003593916,0.001668753,0.001313551,0.00003942061,0.00440212],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006380819,"threshold_uncertainty_score":0.02134597,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2859654360450613,"score_gpt":0.425820200287502,"score_spread":0.1398547642424407,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}